Ins and outs of dendritic cells

International Archives of Allergy and Immunology

Volumn 140, Issue 1, 2006, Pages 53-72

  Schuurhuis, Danita H ^a,b   Fu, Nathalie ^a   Ossendorp, Ferry ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; CD40 CD40L; Cytotoxic T lymphocytes; Dendritic cell; Fc receptor; Maturation; Migration; Th1 Th2 cell; Tumor

Indexed keywords

ANTIBODY; ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; CYTOKINE RECEPTOR; DENDRITIC CELL VACCINE; FC RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ABSENCE OF SIDE EFFECTS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOSKELETON; DENDRITIC CELL; EFFECTOR CELL; ENDOCYTOSIS; ENVIRONMENTAL FACTOR; HUMAN; INNATE IMMUNITY; LYMPHOID ORGAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; HUMANS;

EID: 33645960660     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092002     Document Type: Review

References (258)

1. Reid SD, Penna G, Adorini L: The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000;12:114-121.
2. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997;388:782-787.
3. Flores-Romo L: In vivo maturation and migration of dendritic cells. Immunology 2001;102:255-262.
4. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998;392:245-252.
5. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
6. Van Kooten C, Banchereau J: Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997;9:330-337.
7. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ: The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993;151:2497-2510.
8. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752.
9. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI, Rea D, Offringa R, Geuze HJ, Melief CJ, Ossendorp F: Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 2000;192:145-150.
10. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR: Help for cytotoxicT-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
11. Guerder S, Matzinger P: A fail-safe mechanism for maintaining self-tolerance. J Exp Med 1992;176:553-564.
12. Lanzavecchia A: Immunology. Licence to kill. Nature 1998;393:413-414.
13. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483.
14. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM, Mellman I: Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997;388:787-792.
15. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, Zimmermann VS, Davoust J, Ricciardi-Castagnoli P: Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;185:317-328.
16. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM: Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 1995;181:2237-2247.
17. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A: Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28:2760-2769.
18. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML: T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999;20:561-567.
19. Moser M, Murphy KM: Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199-205.
20. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999;96:1036-1041.
21. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal MR, Liu YJ: Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-1186.
22. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
23. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, Steinman RM: Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487-493.
24. Dallal RM, Lotze MT: The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000;12:583-588.
25. Ardavin C, Martinez DH, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H: Origin and differentiation of dendritic cells. Trends Immunol 2001;22:691-700.
26. Banchereau J, Pulendran B, Steinman R, Palucka K: Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? J Exp Med 2000;192:F39-F44.
27. Ito T, Liu YJ, Kadowaki N: Functional diversity and plasticity of human dendritic cell subsets. Int J Hematol 2005;81:188-196.
28. Robinson SP, Patterson S, English N, Davies D, Knight SC, Reid CD: Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999;29:2769-2778.
29. Borras FE, Matthews NC, Lowdell MW, Navarrete CV: Identification of both myeloid CD11c+ and lymphoid CD11c- dendritic cell subsets in cord blood. Br J Haematol 2001;113:925-931.
30. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-667.
31. Olweus J, BitMansour A, Warnlike R, Thompson PA, Carballido J, Picker LJ, Lund-Johansen F: Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 1997;94:12551-12556.
32. Brigl M, Brenner MB: CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-890.
33. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ: The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997;185:1101-1111.
34. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
35. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
36. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G: High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:741-746.
37. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A: Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001;31:3388-3393.
38. Reis e Sousa C, Sher A, Kaye P: The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 1999;11:392-399.
39. Gilliet M, Liu YJ: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002;195:695-704.
40. De Jong EC, Vieira PL, Kalinski P, Schuitemaker JH, Tanaka Y, Wierenga EA, Yazdanbakhsh M, Kapsenberg ML: Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol 2002;168:1704-1709.
41. Grabbe S, Kampgen E, Schuler G: Dendritic cells: multi-lineal and multi-functional. Immunol Today 2000;21:431-433.
42. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997;90:1920-1926.
43. Macatonia SE, Hsieh CS, Murphy KM, O'Garra A: Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gamma-dependent. Int Immunol 1993;5:1119-1128.
44. Ronchese F, Hausmann B, Le Gros G: Interferon-gamma- and interleukin-4-producing T cells can be primed on dendritic cells in vivo and do not require the presence of B cells. Eur J Immunol 1994;24:1148-1154.
45. Stumbles PA, Thomas JA, Pimm CL, Lee PT, Venaille TJ, Proksch S, Holt PG: Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp Med 1998;188:2019-2031.
46. Tanaka H, Demeure CE, Rubio M, Delespesse G, Sarfati M: Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. J Exp Med 2000;192:405-412.
47. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML: High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 1998;10:1593-1598.
48. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G: Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048.
49. Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML: Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998;161:2804-2809.
50. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA: Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995;181:775-779.
51. Vieira PL, De Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P: Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000;164:4507-4512.
52. Penna G, Sozzani S, Adorini L: Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001;167:1862-1866.
53. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-923.
54. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Gunther G, Johnston I, Lanzavecchia A, Nagasaka T, Okada T, Vermi W, Winkels G, Yamamoto T, Zysk M, Yamaguchi Y, Schmitz J: BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001;194:1823-1834.
55. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001;31:3026-3037.
56. Cella M, Facchetti F, Lanzavecchia A, Colonna M: Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000;1:305-310.
57. Kadowaki N, Antonenko S, Lau JY, Liu YJ: Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000;192:219-226.
58. Bendriss-Vermare N, Burg S, Kanzler H, Chaperot L, Duhen T, de Bouteiller O, D'agostini M, Bridon JM, Durand I, Sederstrom JM, Chen W, Plumas J, Jacob MC, Liu YJ, Garrone P, Trinchieri G, Caux C, Briere F: Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production. J Leukoc Biol 2005;78:954-966.
59. Steinman RM, Inaba K: Myeloid dendritic cells. J Leukoc Biol 1999;66:205-208.
60. Shortman K: Burnet oration: dendritic cells: multiple subtypes, multiple origins, multiple functions. Immunol Cell Biol 2000;78:161-165.
61. Ardavin C: Origin, precursors and differentiation of mouse dendritic cells. Nat Rev Immunol 2003;3:582-590.
62. Manz MG, Traver D, Miyamoto T, Weissman IL, Akashi K: Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 2001;97:3333-3341.
63. Traver D, Akashi K, Manz M, Merad M, Miyamoto T, Engleman EG, Weissman IL: Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. Science 2000;290:2152-2154.
64. Wu L, D'Amico A, Hochrein H, O'Keeffe M, Shortman K, Lucas K: Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 2001;98:3376-3382.
65. Kamath AT, Pooley J, O'Keeffe MA, Vremec D, Zhan Y, Lew AM, D'Amico A, Wu L, Tough DF, Shortman K: The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 2000;165:6762-6770.
66. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, Lira SA, Bravo R: Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of Re1B, a member of the NF-kappa B/Rel family. Cell 1995;80:331-340.
67. Wu L, Nichogiannopoulou A, Shortman K, Georgopoulos K: Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. Immunity 1997;7:483-492.
68. Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, Thielemans K, Leo O, Urbain J, Moser M: CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999;189:587-592.
69. den Haan JM, Lehar SM, Bevan MJ: CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000;192:1685-1696.
70. Iyoda J, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K: The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002;195:1289-1302.
71. Pooley JL, Heath WR, Shortman K: Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol 2001;166:5327-5330.
72. De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, De Baetselier P, Urbain J, Leo O, Moser M: Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996;184:1413-1424.
73. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, Sher A: In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med 1997;186:1819-1829.
74. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C: Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001;22:41-47.
75. Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C, Vicari A, O'Garra A, Biron C, Briere F, Trinchieri G: Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001;2:1144-1150.
76. Bruno L, Seidl T, Lanzavecchia A: Mouse preimmunocytes as non-proliferating multipotent precursors of macrophages, interferon-producing cells, CD8alpha(+) and CD8alpha(-) dendritic cells. Eur J Immunol 2001;31:3403-3412.
77. Nakano H, Yanagita M, Gunn MD: CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001;194:1171-1178.
78. O'Keeffe M, Hochrein H, Vremec D, Scott B, Hertzog P, Tatarczuch L, Shortman K: Dendritic cell precursor populations of mouse blood: identification of the murine homologues of human blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. Blood 2003;101:1453-1459.
79. d'Ostiani CF, Del Sero G, Bacci A, Montagnoli C, Spreca A, Mencacci A, Ricciardi-Castagnoli P, Romani L: Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med 2000;191:1661-1674.
80. Iwasaki A, Kelsall BL: Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999;190:229-239.
81. Khanna A, Morelli AE, Zhong C, Takayama T, Lu L, Thomson AW: Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. J Immunol 2000;164:1346-1354.
82. Diebold SS, Montoya M, Unger H, Alexopoulou L, Roy P, Haswell LE, Al Shamkhani A, Flavell R, Borrow P, Reis e Sousa C: Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003;424:324-328.
83. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F: Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000;1:311-316.
84. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
85. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, Nussenzweig MC: The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995;375:151-155.
86. Kuppner MC, Gastpar R, Gelwer S, Nossner E, Ochmann O, Scharner A, Issels RD: The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol 2001;31:1602-1609.
87. Singh-Jasuja H, Toes RE, Spee P, Munz C, Hilf N, Schoenberger SP, Ricciardi-Castagnoli P, Neefjes J, Rammensee HG, Arnold-Schild D, Schild H: Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000;191:1965-1974.
88. Rudensky AY, Preston-Hurlburt P, al Ramadi BK, Rothbard J, Janeway CA Jr: Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 1992;359:429-431.
89. Kleijmeer MJ, Ossevoort MA, van Veen CJ, van Hellemond JJ, Neefjes JJ, Kast WM, Melief CJ, Geuze HJ: MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J Immunol 1995;154:5715-5724.
90. Kleijmeer MJ, Morkowski S, Griffith JM, Rudensky AY, Geuze HJ: Major histocompatibility complex class II compartments in human and mouse B lymphoblasts represent conventional endocytic compartments. J Cell Biol 1997;139:639-649.
91. Nijman HW, Kleijmeer MJ, Ossevoort MA, Oorschot VM, Vierboom MP, van de Keur M, Kenemans P, Kast WM, Geuze HJ, Melief CJ: Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J Exp Med 1995;182:163-174.
92. Kropshofer H, Hammerling GJ, Vogt AB: How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997;18:77-82.
93. Kropshofer H, Arndt SO, Moldenhauer G, Hammerling GJ, Vogt AB: HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997;6:293-302.
94. Kropshofer H, Vogt AB, Thery C, Armandola EA, Li BC, Moldenhauer G, Amigorena S, Hammerling GJ: A role for HLA-DO as a cochaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 1998;17:2971-2981.
95. Engering AJ, Richters CD, Fluitsma DM, van Pelt AM, Kamperdijk EW, Hoefsmit EC, Pieters J: MHC class II and invariant chain biosynthesis and transport during maturation of human precursor dendritic cells. Int Immunol 1998;10:1713-1723.
96. Neefjes JJ, Ploegh HL: Intracellular transport of MHC class II molecules. Immunol Today 1992;13:179-184.
97. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183:1161-1172.
98. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ: Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998;273:20121-20127.
99. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S: Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001;166:7309-7318.
100. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Mobius W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W: Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 2003;278:10963-10972.
101. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B: Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 2001;247:163-174.
102. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999;147:599-610.
103. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7:297-303.
104. Angelisova P, Hilgert I, Horejsi V: Association of four antigens of the tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins. Immunogenetics 1994;39:249-256.
105. Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME: A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem 1997;272:2595-2598.
106. Rubinstein E, Le Naour F, Lagaudriere-Gesbert C, Billard M, Conjeaud H, Boucheix C: CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 1996;26:2657-2665.
107. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P: The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol 1998;161:3282-3291.
108. Lagaudriere-Gesbert C, Lebel-Binay S, Wiertz E, Ploegh HL, Fradelizi D, Conjeaud H: The tetraspanin protein CD82 associates with both free HLA class I heavy chain and heterodimeric beta 2-microglobulin complexes. J Immunol 1997;158:2790-2797.
109. Imai T, Kakizaki M, Nishimura M, Yoshie O: Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82. J Immunol 1995;155:1229-1239.
110. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000;113:3365-3374.
111. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998;4:594-600.
112. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002;3:1156-1162.
113. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, Pain S, Raposo G, Benaroch P, Bonnerot C: Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol 2002;14:713-722.
114. Harding C, Heuser J, Stahl P: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983;97:329-339.
115. Pan BT, Teng K, Wu C, Adam M, Johnstone RM: Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 1985;101:942-948.
116. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C: TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol 2002;168:3235-3241.
117. Hess C, Sadallah S, Hefti A, Landmann R, Schifferli JA: Ectosomes released by human neutrophils are specialized functional units. J Immunol 1999;163:4564-4573.
118. Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C: Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell 1997;8:2631-2645.
119. Andre F, Andersen M, Wolfers J, Lozier A, Raposo G, Serra V, Ruegg C, Flament C, Angevin E, Amigorena S, Zitvogel L: Exosomes in cancer immunotherapy: prechnical data. Adv Exp Med Biol 2001;495:349-354.
120. van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N, Heyman M: Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001;121:337-349.
121. van Niel G, Heyman M: The epithelial cell cytoskeleton and intracellular trafficking. II. Intestinal epithelial cell exosomes: perspectives on their structure and function. Am J Physiol Gastrointest Liver Physiol 2002;283:G251-G255.
122. Karlsson M, Lundin S, Dahlgren U, Kahu H, Pettersson I, Telemo E: 'Tolerosomes' are produced by intestinal epithelial cells. Eur J Immunol 2001;31:2892-2900.
123. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC)-deri ved exosomes: results of the first phase I clinical trial. J Transl Med 2005;3:10.
124. Pamer E, Cresswell P: Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323-358.
125. Rock KL, Goldberg AL: Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999;17:739-779.
126. Sigal LJ, Crotty S, Andino R, Rock KL: Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
127. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C: Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 1997;27:280-288.
128. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL: Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993;90:4942-4946.
129. Kovacsovics-Bankowski M, Rock KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995;267:243-246.
130. Yewdell JW, Norbury CC, Bennink JR: Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 1999;73:1-77.
131. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR: Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997;186:239-245.
132. Rock KL, Shen L: Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005;207:166-183.
133. Belz GT, Behrens GM, Smith CM, Miller JF, Jones C, Lejon K, Fathman CG, Mueller SN, Shortman K, Carbone FR, Heath WR: The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099-1104.
134. Davey GM, Kurts C, Miller JF, Bouillet P, Strasser A, Brooks AG, Carbone FR, Heath WR: Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J Exp Med 2002;196:947-955.
135. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC: Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-779.
136. Merkenschlager M, Power MO, Pircher H, Fisher AG: Intrathymic deletion of MHC class I-restricted cytotoxic T cell precursors by constitutive cross-presentation of exogenous antigen. Eur J Immunol 1999;29:1477-1486.
137. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, Iyoda T, Ravetch J, Dhodapkar M, Inaba K, Nussenzweig M: Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann NY Acad Sci 2003;987:15-25.
138. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV: Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993;361:359-362.
139. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S: Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-380.
140. Ackerman AL, Kyritsis C, Tampe R, Cresswell P: Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 2003;100:12889-12894.
141. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S: ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003;425:397-402.
142. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault P, Sacks D, Desjardins M: Phagosomes are competent organelles for antigen cross-presentation. Nature 2003;425:402-406.
143. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999;1:362-368.
144. Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-1288.
145. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
146. Shen Z, Reznikoff G, Dranoff G, Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997;158:2723-2730.
147. Rescigno M, Citterio S, Thery C, Rittig M, Medaglini D, Pozzi G, Amigorena S, Ricciardi-Castagnoli P: Bacteria-induced neobiosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci USA 1998;95:5229-5234.
148. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, Verbeek JS, Ossendorp F: Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002;168:2240-2246.
149. Huang AY, Bruce AT, Pardoll DM, Levitsky HI: In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996;4:349-355.
150. Basta S, Stoessel R, Basler M, van den BM, Groettrup M: Cross-presentation of the longlived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 2005;175:796-805.
151. Binder RJ, Srivastava PK: Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005;6:593-599.
152. Fleischer K, Schmidt B, Kastenmuller W, Busch DH, Drexler I, Sutter G, Heike M, Peschel C, Bernhard H: Melanoma-reactive class I-restricted cytotoxic T
153. Shen L, Rock KL: Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci USA 2004;101:3035-3040.
154. Tobian AA, Canaday DH, Boom WH, Harding CV: Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages. J Immunol 2004;172:5277-5286.
155. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-397.
156. Canque B, Camus S, Yagello M, Gluckman JC: IL-4 and CD40 ligation affect differently the differentiation, maturation, and function of human CD34+ cell-derived CD1a+. J Leukoc Biol 1998;64:235-244.
157. Schuurhuis DH, van Montfoort N, Ioan-Facsinay A, Jiawan R, Camps M, Nouta J, Melief CJM, Verbeek JS, Ossendorp F: Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol, in press.
158. Kleijmeer M, Ramm G, Schuurhuis D, Griffith J, Rescigno M, Ricciardi-Castagnoli P, Rudensky AY, Ossendorp F, Melief CJ, Stoorvogel W, Geuze HJ: Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J Cell Biol 2001;155:53-63.
159. Turley SJ, Inaba K, Garrett WS, Ebersold M, Unternaehrer J, Steinman RM, Mellman I: Transport of peptide-MHC class II complexes in developing dendritic cells. Science 2000;288:522-527.
160. Caux C, Ait-Yahia S, Chemin K, de Bouteiller O, Dieu-Nosjean MC, Homey B, Massacrier C, Vanbervliet B, Zlotnik A, Vicari A: Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000;22:345-369.
161. Caux C, Vanbervliet B, Massacrier C, Ait-Yahia S, Vaure C, Chemin K, Dieu-Nosjean And MC, Vicari A: Regulation of dendritic cell recruitment by chemokines. Transplantation 2002;73:S7-11.
162. Sallusto F, Lanzavecchia A: Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000;177:134-140.
163. Medzhitov R, Janeway CA Jr: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9.
164. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-869.
165. Kaisho T, Akira S: Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002;1589:1-13.
166. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM: Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 2001;166:249-255.
167. Kirk P, Bazan JF: Pathogen recognition: TLRs throw us a curve. Immunity 2005;23:347-350.
168. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A: The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005;102:9577-9582.
169. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-1103.
170. Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ: Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 2002;71:538-544.
171. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
172. An H, Xu H, Yu Y, Zhang M, Qi R, Yan X, Liu S, Wang W, Guo Z, Qin Z, Cao X: Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. Immunol Lett 2002;81:165-169.
173. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-9242.
174. Clark GJ, Angel N, Kalo M, Lopez JA, MacDonald K, Vuckovic S, Hart DN: The role of dendritic cells in the innate immune system. Microbes Infect 2000;2:257-272.
175. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999;189:1777-1782.
176. Muzio M, Bosisio D, Polentarutti N, D'amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P, Mantovani A: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000;164:5998-6004.
177. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, Kaisho T, Akira S, Reis e Sousa C: Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003;33:827-833.
178. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ: Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406-17409.
179. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-451.
180. Underhill DM, Ozinsky A, Smith KD, Aderem A: Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA 1999;96:14459-14463.
181. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D: Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999;163:1-5.
182. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A: Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999;189:821-829.
183. Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJ, Brand A, Goulmy E: Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999;163:57-61.
184. Dabbagh K, Dahl ME, Stepick-Biek P, Lewis DB: Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J Immunol 2002;168:4524-4530.
185. da Silva CJ, Soldau K, Christen U, Tobias PS, Ulevitch RJ: Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001;276:21129-21135.
186. Fenton MJ, Golenbock DT: LPS-binding proteins and receptors. J Leukoc Biol 1998;64:25-32.
187. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K: Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 2000;164:3471-3475.
188. Visintin A, Mazzoni A, Spitzer JA, Segal DM: Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci USA 2001;98:12156-12161.
189. Beutler B: Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000;12:20-26.
190. Lane PJ, Brocker T: Developmental regulation of dendritic cell function. Curr Opin Immunol 1999;11:308-313.
191. Sweet MJ, Campbell CC, Sester DP, Xu D, McDonald RC, Stacey KJ, Hume DA, Liew FY: Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J Immunol 2002;168:392-399.
192. Mizel SB, Snipes JA: Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5. J Biol Chem 2002;277:22414-22420.
193. Grewal IS, Flavell RA: A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 1996;17:410-414.
194. Stout RD, Suttles J: The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996;17:487-492.
195. Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE: The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med 2000;78:363-371.
196. Luft T, Jefford M, Luetjens P, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E: IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J Immunol 2002;168:713-722.
197. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ: T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002;168:2720-2728.
198. Van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
199. French RR, Chan HT, Tutt AL, Glennie MJ: CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-553.
200. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998;393:474-478.
201. Behrens GM, Li M, Davey GM, Allison J, Flavell RA, Carbone FR, Heath WR: Helper requirements for generation of effector CTL to islet beta cell antigens. J Immunol 2004;172:5420-5426.
202. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV: FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005;23:41-51.
203. Ravetch JV, Holland S: IgG Fc receptors. Annu Rev Immunol 2001;19:275-290.
204. Hulett MD, Hogarth PM: The second and third extracellular domains of FcgammaRI (CD64) confer the unique high affinity binding of IgG2a. Mol Immunol 1998;35:989-996.
205. Amigorena S, Bonnerot C: Fc receptor signaling and trafficking: a connection for antigen processing. Immunol Rev 1999;172:279-284.
206. Amigorena S, Bonnerot C: Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol 1999;11:385-390.
207. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, Adema GJ, Punt CJ, Figdor CG: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12-17.
208. Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli AM, Malorni W, Fais S, Belardelli F: Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001;98:3022-3029.
209. Sozzani S: Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev 2005;16:581-592.
210. Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y: EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998;161:3096-3102.
211. Chen Z, Dehm S, Bonham K, Kamencic H, Juurlink B, Zhang X, Gordon JR, Xiang J: DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001;214:60-71.
212. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster J, Xu Y, Nooyen P, McClanahan T, Bacon KB, Figdor CG: A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997;387:713-717.
213. Katou F, Ohtani H, Nakayama T, Ono K, Matsushima K, Saaristo A, Nagura H, Yoshie O, Motegi K: Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am J Pathol 2001;158:1263-1270.
214. Kikuchi T, Crystal RG: Antigen-pulsed dendritic cells expressing macrophage-derived chemokine elicit Th2 responses and promote specific humoral immunity. J Clin Invest 2001;108:917-927.
215. Kellermann SA, Hudak S, Oldham ER, Liu YJ, McEvoy LM: The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999;162:3859-3864.
216. Dieu-Nosjean MC, Vicari A, Lebecque S, Caux C: Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 1999;66:252-262.
217. Yoneyama H, Matsuno K, Matsushimaa K: Migration of dendritic cells. Int J Hematol 2005;81:204-207.
218. Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis e Sousa C: CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000;13:453-462.
219. Janeway CA Jr: The immune system evolved to discriminate infectious nonself from non-infectious self. Immunol Today 1992;13:11-16.
220. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
221. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK: Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000;12:1539-1546.
222. Steinman RM, Turley S, Mellman I, Inaba K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-416.
223. Steinman RM, Nussenzweig MC: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002;99:351-358.
224. Huang FP, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, MacPherson GG: A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000;191:435-444.
225. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-434.
226. Scheinecker C, McHugh R, Shevach EM, Germain RN: Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002;196:1079-1090.
227. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
228. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1222.
229. Trinchieri G: Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243.
230. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R: Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-282.
231. Melief CJ, van der Burg SH, Toes RE, Ossendorp F, Offringa R: Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 2002;188:177-182.
232. Melief CJ: Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003;33:2645-2654.
233. van Mierlo GJ, Boonman ZF, Dumortier HM, Den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ: Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 2004;173:6753-6759.
234. Dumortier H, van Mierlo GJ, Egan D, van Ewijk W, Toes RE, Offringa R, Melief CJ: Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function. J Immunol 2005;175:855-863.
235. Esche C, Lokshin A, Shurin GV, Gastman BR, Rabinowich H, Watkins SC, Lotze MT, Shurin MR: Tumor's other immune targets: dendritic cells. J Leukoc Biol 1999;66:336-344.
236. Esche C, Shurin GV, Kirkwood JM, Wang GQ, Rabinowich H, Pirtskhalaishvili G, Shurin MR: Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res 2001;7:974s-979s.
237. Timmerman JM, Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507-529.
238. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N: Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-1368.
239. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
240. Knight SC, Hunt R, Dore C, Medawar PB: Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985;82:4495-4497.
241. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
242. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
243. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD: Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-3661.
244. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
245. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995;18:86-94.
246. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182:255-260.
247. Zitvogel L, Mayordomo JI, Tjandrawan T, Deleo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines. J Exp Med 1996;183:87-97.
248. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-322.
249. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-2926.
250. Becker Y: Dendritic cell activity against primary tumors: an overview. In Vivo 1993;7:187-191.
251. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
252. Austyn JM: Dendritic cells. Curr Opin Hematol 1998;5:3-15.
253. Bell D, Young JW, Banchereau J: Dendritic cells. Adv Immunol 1999;72:255-324.
254. De Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG: Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002;25:429-438.
255. De Vries IJ, Adema GJ, Punt CJ, Figdor CG: Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med 2005;109:113-126.
256. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-151.
257. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
258. Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480.